Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma

Cisplatin is the first-line chemotherapeutic agent for the treatment of oral squamous cell carcinoma (OSCC). However, the intrinsic or acquired resistance against cisplatin remains a major obstacle to treatment efficacy in OSCC. Recently, mitochondrial DNA (mtDNA) alterations have been reported in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Aminuddin, Amnani, Ng, Pei Yuen, Leong, Chee-Onn, Chua, Eng Wee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217862/
https://www.ncbi.nlm.nih.gov/pubmed/32398775
http://dx.doi.org/10.1038/s41598-020-64664-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217862/
https://www.ncbi.nlm.nih.gov/pubmed/32398775
http://dx.doi.org/10.1038/s41598-020-64664-3

Ejemplares similares